Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrel

Qian Gu, Qin Wang, Rui Hua, Wenhao Zhang, Jianzhen Teng, Jiazheng Ma, Zhou Dong, Xiaoxuan Gong, Chunjian LiJournal of Biomedical Research 2023 · DOI

Abstract

High on-treatment platelet reactivity (HOPR) remains a significant challenge for patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). While genetic factors are known to influence clopidogrel response, they do not account for all cases. This study identifies low red blood cell (RBC) counts as a novel, independent predictor of HOPR, offering a potential clinical marker for identifying high-risk patients.

Introduction

Cardiovascular disease remains the leading cause of death globally, with coronary artery disease (CAD) responsible for approximately half of these fatalities. For patients with CAD who undergo percutaneous coronary intervention (PCI), the management of thrombotic risk is paramount. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the standard pharmacological intervention to prevent stent thrombosis and recurrent ischemic events.

Clopidogrel is one of the most widely prescribed P2Y12 inhibitors due to its established efficacy and safety profile. However, a significant clinical challenge persists: up to 30% of patients treated with standard doses of clopidogrel exhibit High On-treatment Platelet Reactivity (HOPR). In these individuals, the medication fails to adequately suppress platelet activity, leaving them at a significantly higher risk for recurrent heart attacks or cardiac death. While polymorphisms in the CYP2C19 gene are recognized contributors to this variability, they explain only about 12% of HOPR cases. Identifying other clinical factors is crucial for refining personalized antiplatelet strategies and addressing this residual ischemic risk.

Methods

This cross-sectional cohort study analyzed 1,649 CAD patients who underwent PCI at the First Affiliated Hospital of Nanjing Medical University. All participants had been on a stable dual antiplatelet regimen of clopidogrel (75 mg/day) and aspirin (100 mg/day) for at least five days prior to testing.

Platelet reactivity was assessed using Light Transmission Aggregometry (LTA), which is considered the clinical gold standard for measuring platelet function. Venous blood samples were collected two hours after drug administration. Platelet aggregation was induced by adenosine diphosphate (ADP) at a final concentration of 5 μmol/L. HOPR was defined as a maximum platelet aggregation (PL<sub>ADP</sub>) exceeding 40%. The research team utilized both univariable and multivariable logistic regression models to identify clinical variables independently associated with poor drug response.

Results

Among the 1,649 patients in the cohort, 23.6% (389 patients) were identified as having HOPR. After adjusting for potential confounders, multivariable analysis identified three key independent predictors of high platelet reactivity:

  • Red Blood Cell (RBC) Count: Higher RBC counts were significantly associated with a lower risk of HOPR (OR = 0.480, 95% CI: 0.302–0.763, P = 0.002). This indicates that patients with lower RBC counts are more likely to experience clopidogrel resistance.
  • Body Mass Index (BMI): Increased BMI was linked to higher platelet reactivity (OR = 1.140, 95% CI: 1.054–1.232, P = 0.001), possibly due to altered drug metabolism or under-dosing in larger patients.
  • Statin Consumption: Patients taking statins were significantly more likely to exhibit HOPR (OR = 4.504, 95% CI: 1.004–20.208, P = 0.049).

Discussion

The inverse relationship between RBC count and platelet reactivity suggests that RBCs play a more active role in hemostasis than previously recognized. The authors propose a biological mechanism involving Nitric Oxide (NO). RBCs are known to produce and release NO, a potent endogenous inhibitor of platelet activation. A reduction in RBC mass might lead to a localized deficiency in NO bioavailability, thereby failing to provide the necessary inhibitory signal to complement the medication's effect.

Furthermore, the association with statins likely stems from competitive inhibition. Both statins and clopidogrel are metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme. Concurrent use may reduce the efficiency of clopidogrel's conversion into its active metabolite, thereby diminishing its antiplatelet efficacy.

Conclusion

Low RBC count is a significant independent predictor of HOPR in CAD patients treated with clopidogrel following PCI. While the absolute differences in RBC counts between groups were subtle, this finding highlights the importance of considering basic hematological parameters when assessing ischemic risk. Future research should investigate whether tailoring antiplatelet therapy—perhaps by utilizing more potent agents like ticagrelor in patients with low RBC counts—can improve clinical outcomes for this high-risk subgroup.

Summary updated

Abstract

Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrel Dear Editor, Cardiovascular disease is the leading cause of deaths worldwide, with coronary artery disease (CAD) accounting for approximately 50% of its mortality.Dual antiplatelet therapy, including aspirin and a P2Y 12 inhibitor, is the most important treatment for CAD patients undergoing percutaneous coronary intervention (PCI) to prevent recurrent ischemic events and cardiac death.Clopidogrel is one of the commonly used P2Y 12 inhibitors.However, up to 30% of patients treated with a standard dose of clopidogrel present with high on-treatment platelet reactivity (HOPR), which is associated with the increased ischemic risks [1] .The causes of HOPR are multifactorial and complex.Polymorphisms of cytochrome P450 enzyme genes (such as CYP2C19) have been widely reported to influence platelet response to clopidogrel [2] , which, however, may account for only 12% of HOPR [2] .The etiology for the rest of the patients exhibiting HOPR remains uncertain, which is a residual ischemic risk for CAD patients who are taking clopidogrel.The present study aims to investigate risk factors associated with HOPR in CAD patients undergoing PCI and receiving the dual antiplatelet therapy with aspirin and clopidogrel.The present study is a cross-sectional cohort study performed in the First Affiliated Hospital of Nanjing Medical University using our pre-registered database (Unique Identifier: NCT01968499), complied with the Helsinki declaration and local regulations, and was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University (No. 2011-SRFA-099).A written informed consent was obtained from each patient.CAD patients who had undergone PCI and taken clopidogrel (75 mg/day) combined with aspirin (100 mg/day) for more than five days were consecutively enrolled between April 2011 and October 2016 in the coronary care unit of the First Affiliated Hospital of Nanjing Medical University.We excluded patients who were: (1) intolerant to aspirin or clopidogrel;(2) with hematological diseases;(3) with baseline hemoglobin < 90 g/L, or platelet count < 80 10 9 /L or > 450 10 9 /L; (4) taking other antiplatelet agents or anticoagulants or any drugs that could potentially interfere with the antiplatelet efficacy of the study drugs; and (5) with end-stage diseases (e.g., cancer) or other conditions that were inappropriate to be recruited at the discretion of the investigators.The patients' demographics, present disease history, past disease history, personal history, physical examination, laboratory examination, and medications were recorded.In addition, venous blood was collected into two 2.7 mL vacutainer tubes containing 3.2% sodium citrate two hours after the patients took clopidogrel and aspirin.Platelet reactivities were measured by the light transmission aggregometry within two hours of the sampling.Platelet-rich plasma (PRP) was separated by centrifuging the blood sample at 200 g at 22 for 5 min, and platelet poor plasma (PPP) was obtained by spinning the remaining blood at 2 465 g for another 10 min.Platelet counts were adjusted by adding PPP to PRP to achieve a count of 250 10 9 /L.A total of 500 L adjusted PRP was tested by a Chronolog aggregometer (Model 700, Chrono-log Corporation, Havertown, PA, USA) with 500 L PPP as control.Platelet aggregation was induced by 2.5 L adenosine diphosphate (ADP) with a final concentration of 5 mol/L or 10 L arachidonic acid (AA) with a final
BibTeX
@article{gu2023low,
  author = {Qian Gu and Qin Wang and Rui Hua and Wenhao Zhang and Jianzhen Teng and Jiazheng Ma and Zhou Dong and Xiaoxuan Gong and Chunjian Li},
  title = {{Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrel}},
  journal = {Journal of Biomedical Research},
  year = {2023},
  doi = {10.7555/jbr.37.20230035},
}
Figure